9853 Pacific Heights Blvd.
Suite D. San Diego,
CA 92121, USA
Tel: 858-263-4982
Email: info@abeomics.com

32-2318: FBL Recombinant Protein

Alternative Name : rRNA 2'-O-methyltransferase fibrillarin,34 kDa nucleolar scleroderma antigen,FBL,FIB1,FLRN,fibrillarin,FIB,RNU3IP1.

Description

Source : Escherichia Coli. FBL Human Recombinant fused with 23 amino acid His tag at N-terminus produced in E.Coli is a single, non-glycosylated, polypeptide chain containing 262 amino acids (83-321 a.a.) and having a molecular mass of 28.9kDa. The FBL is purified by proprietary chromatographic techniques. FBL is a significant small nucleolar protein in eukaryotes, which has an essential role in pre-rRNA processing during ribosomal biogenesis. Fibrillarin is a component of several ribonucleoproteins including a nucleolar small nuclear ribonucleoprotein (SnRNP) and one of the two classes of small nucleolar ribonucleoproteins (snoRNPs). Fibrillarin contains an N-terminal repetitive domain which is rich in glycine and arginine residues, like fibrillarins in other species. Fibrillarin's central region is similar to an RNA-binding domain and contains an RNP consensus sequence. FBL is linked to the U3, U8, and U13 small nuclear RNAs and is positioned in the dense fibrillar component (DFC) of the nucleolus. Antisera from roughly 8% of humans with the autoimmune disease scleroderma recognize fibrillarin.

Product Info

Amount :	20 µg
Purification :	Greater than 85.0% as determined by SDS-PAGE.
Content :	The FBL solution (0.5 mg/ml) contains 20mM Tris-HCl buffer (pH 8.0), 20% glycerol, 1mM DTT, 0.2M NaCl and 1mM EDTA.
Storage condition :	Store at 4°C if entire vial will be used within 2-4 weeks.Store, frozen at -20°C for longer periods of time. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA).Avoid multiple freeze-thaw cycles.
Amino Acid :	MGSSHHHHHH SSGLVPRGSH RSMGKNVMVE PHRHEGVFIC RGKEDALVTK NLVPGESVYG EKRVSISEGD DKIEYRAWNP FRSKLAAAIL GGVDQIHIKP GAKVLYLGAA SGTTVSHVSD IVGPDGLVYA VEFSHRSGRD LINLAKKRTN IIPVIEDARH PHKYRMLIAM VDVIFADVAQ PDQTRIVALN AHTFLRNGGH FVISIKANCI DSTASAEAVF ASEVKKMQQE NMKPQEQLTL EPYERDHAVV VGVYRPPPKV KN.